AstraZeneca Pharma India Ltd has closed its trading window for dealing in its equity shares starting June 16, 2026. The closure is intended to prevent insider trading and ensure compliance with regulatory standards ahead of its quarterly financial announcement. The window will remain shut until 48 hours after the company declares its unaudited financial results for the quarter ending June 30, 2026.

Regulatory Compliance

The decision to close the trading window aligns with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. Additionally, the move adheres to astrazeneca pharma 's internal Code of Conduct for Prevention of Insider Trading. These regulations mandate a blackout period to restrict trading by designated insiders when they are in possession of unpublished price-sensitive information.

Timeline for Reopening

The trading window will not reopen immediately upon the release of the Q1FY27 results. Instead, it will remain closed for an additional 48 hours following the declaration of the unaudited financial results. This buffer period is standard practice to allow the information to be fully assimilated by the market before trading resumes for insiders.

The company has communicated this schedule to the National Stock Exchange of India Ltd and BSE Limited to ensure the information is on public record.

AstraZeneca Pharma India Ltd has accepted the resignations of two senior management personnel, Ms. Aditi Mehta and Mr. Srikanth B.S., who are leaving to pursue career opportunities outside the organisation. The departures were disclosed in a regulatory filing submitted on June 12, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The exits impact key leadership functions within the Oncology Business Unit and India Operations.

Senior Leadership Departures

Ms. Aditi Mehta served as Business Unit Director of the Oncology Business Unit. She completed her handover period and was relieved from her duties effective the close of business hours on June 12, 2026. The company stated that it is in the process of identifying a suitable replacement to ensure continuity in its oncology operations.

Mr. Srikanth B.S. held the position of Site Lead, India Operations. He will be relieved following the completion of his handover period, with his cessation effective the close of business hours on June 15, 2026. No specific details regarding the recruitment process for his role were disclosed in the filing.

Resignation Details at a Glance

The following table summarises the key details of both resignations as disclosed in the regulatory filing:

Regulatory Compliance

The filing was signed by Tanya Sanish, Company Secretary and Compliance Officer of AstraZeneca Pharma India Limited. The disclosures were made in accordance with SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/2026 dated January 30, 2026.